Research programme: CD26 antigen antagonists - Eisai

Drug Profile

Research programme: CD26 antigen antagonists - Eisai

Latest Information Update: 25 Jul 2007

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 25 Jul 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in Japan (unspecified route)
  • 14 Sep 2004 Preclinical trials in Type-2 diabetes mellitus in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top